Objective {#Sec1}
=========

The understanding of complex multifactorial diseases requires the availability of information for thousands of affected individuals. The release of this data is an attempt to contribute to studies of remittent recurrent multiple-sclerosis (RRMS). The sequencing data presented here was generated to help the identification of genomic variants located in the exomes of RRMS patients from Brazil, a country with elevated ethnic admixture \[[@CR1]--[@CR3]\]. Exomes of the patient's first-degree unaffected relatives (both parents and siblings) were also sequenced to allow the study of 'de novo' variations which, so far, have been under investigated in RRMS. The exome variations observed here may help the study of relevant single nucleotide polymorphisms, de novo- and structural genomic variations---such as copy-number alterations that may be associated with the disease \[[@CR4]--[@CR8]\]. In total, 28 individuals have been sequenced including eight RRMS patients as well as a set of another 20 unaffected first-degree relatives. Some variations suggested by these data have been validated by Sanger sequencing and subjected to functional analysis, have been presented in a manuscript that is currently under review (Garcia-Rosa, et al. unpublished). Most of the exomes presented here have not been explored yet, but it is certain that the whole dataset can be useful for subsequent studies by other groups interested in this field.

Data description {#Sec2}
================

This study was focused on families containing one member diagnosed with RRMS, with both biological parents alive, and no description of other cases of neurodegenerative or neuropsychiatric cases in the family. Subjects were diagnosed as RRMS patients by experienced neurologists, using currently accepted protocols \[[@CR9]\]; paternity and maternity were confirmed for all families using the Variant Call Format (VCFs) files to verify the compatibility status of single nucleotide polymorphisms for all patients and their siblings, according to their status in the exomes of the parents \[[@CR10]\]. The study comprised a total of 28 Brazilian individuals, divided in eight families. The trio mother--patient--father was available for all eight families and four of the families also included one unaffected sibling. According to this, subjects were designated in familial groups (G) from G1 to G8. For each family group (G), individuals were classified with single letters designating the mother (M), the father (F) and the patient (P), as well as the unaffected patient--brother (B) or the unaffected patient--sister (S). Therefore, G1F indicates the exome sequence of the father of group 1 and G5S indicates the exome sequence of the unaffected sister of the patient of family 5, and so forth. For each subject, genomic DNA was obtained from leukocytes isolated from 4 mL samples of peripheral whole blood using the Wizard Genomic DNA purification kit (Promega, USA). One microgram of genomic DNA samples from eight affected individuals (G1P to G8P), their parents (16 samples: G1 M to G8 M for mothers and G1F to G8F for fathers) as well as four siblings (G2B, G4S, G5S and G6S) were prepared for WES (whole exome sequencing) using the Ion TargetSeq Exome Capture Kit (Thermo Fisher, USA). For this, the DNA was fragmented for 30 min (Ion Shear Plus Enzyme Mix II), adapters and barcodes were ligated and size selected (275--295 bp). Libraries were amplified (8 cycles) using the Platinum PCR Super Mix High Fidelity. Exons were captured from 500 ng of amplified libraries by hybridization using biotinylated probes (Ion-TargetSeq-Exome-50 Mb-hg19_RevA), following the manufacturer's instructions. This panel covers a total of 46.2 million bases, encompassing 25,313 genes and 267,049 targets. The instructions to access and to download the corresponding target regions (.bed files) of this specific panel are provided by the manufacturer \[[@CR11]\].

WES libraries were sequenced using the Ion PI Sequencing 200 kit V3 in the Ion Proton sequencing platform (CIPE, A.C.Camargo Cancer Center, São Paulo, SP, Brazil). On average, each sequencing run in a P1 chip generated about 10--12 billion mapped bases. Sequencing reads were mapped against the specific exome target region (Ion-TargetSeq-Exome-50 Mb-hg19_revA), using the configuration TargetSeq---Proton---Germ Line---High Stringency, and the Torrent Suite V4.2.1. For each individual exome we generated an average of 66.1 million good quality mapped reads with an average length of \~ 160 nt. On average, for 90% of the exome we reached a vertical coverage of at least 20×. The data described in the present report has not been filtered prior to deposition in the short reads archive (/sra) of NCBI, therefore, mapped and unmapped reads are available through the provided links shown in Table [1](#Tab1){ref-type="table"}.Table 1Overview of data files/data setsLabelName of data fileFile types (file extension)Data repository and identifier (DOI or accession number)LicenseData file 1SAMN07947504--G1MBinary sequence alignment/map file (.bam)Sequence Read Archive\
<http://www.ncbi.nlm.nih.gov/sra> (SRP122913)CC-BYData file 2SAMN07947505--G1PData file 3SAMN07947506--G1FData file 4SAMN07947507--G2BData file 5SAMN07947508--G2MData file 6SAMN07947509--G2PData file 7SAMN07947510--G2FData file 8SAMN07947511--G3MData file 9SAMN07947512--G3PData file 10SAMN07947513--G3FData file 11SAMN07947514--G4SData file 12SAMN07947515--G4MData file 13SAMN07947516--G4PData file 14SAMN07947517--G4FData file 15SAMN07947518--G5SData file 16SAMN07947519--G5MData file 17SAMN07947520--G5PData file 18SAMN07947521--G5FData file 19SAMN07947522--G6SData file 20SAMN07947523--G6MData file 21SAMN07947524--G6PData file 22SAMN07947525--G6FData file 23SAMN07947526--G7MData file 24SAMN07947527--G7PData file 25SAMN07947528--G7FData file 26SAMN07947529--G8MData file 27SAMN07947530--G8PData file 28SAMN07947531--G8F

Limitations {#Sec3}
===========

The sequencing platform used here generates high quality reads, but homopolymeric regions---the consecutive repetition of the same nucleotide for five times or more---have been shown to contain higher error rates that affect the length of the repetitive unit \[[@CR12]\]. Previous work recommended that variants located in the junction of two homopolymers, as well as variants that indicate the elongation (insertions) or the shortening (deletions) of homopolymeric repeats, should be confirmed by Sanger sequencing \[[@CR12]\]. Therefore, variants in homopolymeric regions identified in our data should be evaluated with extra caution. Compared to other Next Generation Sequencing platforms, such as Illumina, the platform used here presents higher error rates in variants identified as small insertions and deletions (InDels). Also, as the number of individuals sequenced here is small, investigators should seek more data and experimental validation to help identifying genomic alterations that might be associated with RRMS.
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